{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"38","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"Acute GVHD grade III-IV\n\nSummarized using standard descriptive statistics along with corresponding 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan\\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.\n\nNote: \\*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.","id":"OG000","title":"Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"Up to day 100","title":"Acute GVHD Grade III-IV","type":"SECONDARY","unitOfMeasure":"percentage of participants"}